Table 2 The results of univariate analysis of overall survival (n = 196). Values are mean ± SD or n (%)

Age, years

60.44 ± 10.14

1.01 (0.99, 1.04) 0.1624

Female

70 (35.71%)

0.60 (0.38, 0.92) 0.0201

Never smoker

69 (35.20%)

1.08 (0.72, 1.64) 0.7038

Hypertension

66 (33.67%)

1.11 (0.74, 1.68) 0.6070

Leukocyte, 10⁹/L

7.07 ± 2.57

1.04 (0.96, 1.11) 0.3226

Neutrophil, 10⁹/L

4.97 ± 2.21

1.05 (0.96, 1.14) 0.2963

Lymphocyte, 10⁹/L

1.31 ± 0.55

0.90 (0.63, 1.28) 0.5478

Platelets, 10⁹/L

256.67 ± 98.46

1.00 (1.00, 1.00) 0.2259

Albumin, g/L

41.84 ± 4.65

0.92 (0.88, 0.95) < 0.0001

Globulin, g/L

28.51 ± 4.97

1.01 (0.97, 1.05) 0.7345

AGR

1.52 ± 0.33

0.47 (0.26, 0.84) 0.0105

ALK rearrangement

No

136 (69.39%)

1.0

Yes

3 (1.53%)

0.89 (0.21, 3.71) 0.8743

Unknown

57 (29.08%)

1.00 (0.64, 1.55) 0.9866

EGFR mutation

No

83 (42.35%)

1.0

Yes

57 (29.08%)

0.90 (0.56, 1.46) 0.6706

Unknown

56 (28.57%)

0.92 (0.57, 1.50) 0.7518

Histology

Adenocarcinoma

124 (63.27%)

1.0

Squamous cell carcinoma

47 (23.98%)

0.89 (0.55, 1.45) 0.6430

Others

25 (12.76%)

0.81 (0.43, 1.53) 0.5158

Tumor stage

III

30 (15.31%)

1.0

IV

166 (84.69%)

1.67 (0.91, 3.07) 0.0964

ECOG PS score

0

136 (69.39%)

1.0

1

60 (30.61%)

1.17 (0.75, 1.82) 0.4810

Number of metastases

<3

153 (78.06%)

1.0

≥3

43 (21.94%)

1.49 (0.94, 2.37) 0.0886

Number of previous treatment lines

<3

107 (54.59%)

1.0

≥3

89 (45.41%)

1.08 (0.73, 1.61) 0.6975

Number of previous chemotherapy lines

≤2

153 (78.06%)

1.0

>2

43 (21.94%)

0.93 (0.58, 1.49) 0.7676

Previous targeted therapy

69 (35.20%)

1.15 (0.76, 1.74) 0.5034

Previous radiotherapy

35 (17.86%)

0.72 (0.42, 1.24) 0.2364

Previous immunotherapy

32 (16.33%)

1.08 (0.63, 1.84) 0.7910

Anlotinib monotherapy

156 (79.59%)

0.93 (0.55, 1.59) 0.7998